For the past two weeks, we’ve been discussing the efficacy rates of Chinese vaccines compared to those from other countries and a number of readers have asked for comparative data to measure how jabs from the likes of Sinovac perform against AstraZeneca’s in particular.

Sinovac’s jab that uses inactive agents performs poorly against the more advanced mRNA vaccines from Pfizer, Moderna, and even Russia’s Sputnik V in phase three clinical trials. However, that 50% efficacy rate for Sinovac is only for mild cases. In terms of severe illness or death, it performs at almost 100% which is critical for developing countries because it lowers hospital admission rates.